BR112012008485A2 - composto, formulação farmacêutica, uso de um composto, processo para a fabricação do composto de formula e compostos, processos, formulações e usos - Google Patents
composto, formulação farmacêutica, uso de um composto, processo para a fabricação do composto de formula e compostos, processos, formulações e usosInfo
- Publication number
- BR112012008485A2 BR112012008485A2 BR112012008485A BR112012008485A BR112012008485A2 BR 112012008485 A2 BR112012008485 A2 BR 112012008485A2 BR 112012008485 A BR112012008485 A BR 112012008485A BR 112012008485 A BR112012008485 A BR 112012008485A BR 112012008485 A2 BR112012008485 A2 BR 112012008485A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- formulations
- compounds
- manufacture
- processes
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 4
- 238000000034 method Methods 0.000 title 2
- 238000009472 formulation Methods 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25141309P | 2009-10-14 | 2009-10-14 | |
| US34562610P | 2010-05-18 | 2010-05-18 | |
| PCT/EP2010/065159 WO2011045257A1 (en) | 2009-10-14 | 2010-10-11 | Novel n-substituted-pyrrolidines as inhibitors of mdm2-p-53 interactions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012008485A2 true BR112012008485A2 (pt) | 2019-09-24 |
Family
ID=43567698
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012008485A BR112012008485A2 (pt) | 2009-10-14 | 2010-10-11 | composto, formulação farmacêutica, uso de um composto, processo para a fabricação do composto de formula e compostos, processos, formulações e usos |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8017607B2 (OSRAM) |
| EP (1) | EP2488491A1 (OSRAM) |
| JP (1) | JP2013507416A (OSRAM) |
| KR (1) | KR20120081210A (OSRAM) |
| CN (1) | CN102548963A (OSRAM) |
| AU (1) | AU2010305914A1 (OSRAM) |
| BR (1) | BR112012008485A2 (OSRAM) |
| CA (1) | CA2774512A1 (OSRAM) |
| IL (1) | IL218018A0 (OSRAM) |
| IN (1) | IN2012DN02487A (OSRAM) |
| MX (1) | MX2012003982A (OSRAM) |
| WO (1) | WO2011045257A1 (OSRAM) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8889632B2 (en) | 2007-01-31 | 2014-11-18 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
| US8592377B2 (en) | 2007-03-28 | 2013-11-26 | President And Fellows Of Harvard College | Stitched polypeptides |
| US8354444B2 (en) * | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
| US20110118283A1 (en) * | 2009-11-17 | 2011-05-19 | Qingjie Ding | Substituted Pyrrolidine-2-Carboxamides |
| WO2012021876A2 (en) | 2010-08-13 | 2012-02-16 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| WO2012076513A1 (en) * | 2010-12-09 | 2012-06-14 | F. Hoffmann-La Roche Ag | 3-cyano-1-hydroxymethyl-2-phenylpyrrolidine derivatives as inhibitors of mdm2-p53 interactions useful for the treatment of cancer |
| SG193002A1 (en) | 2011-03-10 | 2013-09-30 | Daiichi Sankyo Co Ltd | Dispiropyrrolidine derivative |
| CN108929375A (zh) | 2011-10-18 | 2018-12-04 | 爱勒让治疗公司 | 拟肽大环化合物 |
| WO2013123267A1 (en) | 2012-02-15 | 2013-08-22 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
| RU2642299C2 (ru) | 2012-02-15 | 2018-01-24 | Эйлерон Терапьютикс, Инк. | P53 пептидомиметические макроциклы |
| TWI586668B (zh) | 2012-09-06 | 2017-06-11 | 第一三共股份有限公司 | 二螺吡咯啶衍生物之結晶 |
| US9604919B2 (en) | 2012-11-01 | 2017-03-28 | Aileron Therapeutics, Inc. | Disubstituted amino acids and methods of preparation and use thereof |
| BR112015013611A2 (pt) | 2012-12-20 | 2017-11-14 | Merck Sharp & Dohme | composto, e, composição farmacêutica |
| AU2015320545C1 (en) | 2014-09-24 | 2020-05-14 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and formulations thereof |
| KR20170058424A (ko) | 2014-09-24 | 2017-05-26 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티드모방 거대고리 및 이의 용도 |
| MX2017011834A (es) | 2015-03-20 | 2018-04-11 | Aileron Therapeutics Inc | Macrociclos peptidomimeticos y usos de los mismos. |
| EP3347372A4 (en) | 2015-09-10 | 2019-09-04 | Aileron Therapeutics, Inc. | PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1 |
| CN109152843A (zh) | 2016-05-20 | 2019-01-04 | 豪夫迈·罗氏有限公司 | Protac抗体缀合物及其使用方法 |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
| WO2024240858A1 (en) | 2023-05-23 | 2024-11-28 | Valerio Therapeutics | Protac molecules directed against dna damage repair system and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0947511A1 (en) | 1998-03-30 | 1999-10-06 | F. Hoffmann-La Roche Ag | Derivatives of phenoxy acetic acid and of phenoxymethyl tetrazole having antitumor activity |
| SK822002A3 (en) | 1999-07-21 | 2002-09-10 | Astrazeneca Ab | New compounds |
| WO2005099687A2 (en) | 2004-04-09 | 2005-10-27 | President And Fellows Of Harvard College | Analogs of salinosporamide a |
| US7423051B2 (en) | 2004-07-15 | 2008-09-09 | Hoffmann-La Roche Inc. | 2,6-diaminopyridine derivatives |
| MX2007010272A (es) | 2005-02-22 | 2008-03-12 | Univ Michigan | Inhibidores de moleculas pequenas de mdm2 y usos de los mismos. |
| AU2007207052B2 (en) | 2006-01-18 | 2012-07-12 | F. Hoffmann-La Roche Ag | CIS-4, 5-biaryl-2-heterocyclic-imidazolines as MDM2 inhibitors |
| KR20090042779A (ko) | 2006-06-30 | 2009-04-30 | 쉐링 코포레이션 | Ｐ53 활성을 증가시키는 치환된 피페리딘 및 이의 사용 |
| MY160424A (en) | 2008-09-18 | 2017-03-15 | Hoffmann La Roche | Substituted pyrrolidine-2-carboxyamides. |
-
2010
- 2010-10-06 US US12/898,974 patent/US8017607B2/en not_active Expired - Fee Related
- 2010-10-11 CA CA2774512A patent/CA2774512A1/en not_active Abandoned
- 2010-10-11 AU AU2010305914A patent/AU2010305914A1/en not_active Abandoned
- 2010-10-11 EP EP10768450A patent/EP2488491A1/en not_active Withdrawn
- 2010-10-11 JP JP2012533592A patent/JP2013507416A/ja active Pending
- 2010-10-11 MX MX2012003982A patent/MX2012003982A/es not_active Application Discontinuation
- 2010-10-11 WO PCT/EP2010/065159 patent/WO2011045257A1/en active Application Filing
- 2010-10-11 IN IN2487DEN2012 patent/IN2012DN02487A/en unknown
- 2010-10-11 CN CN2010800461741A patent/CN102548963A/zh active Pending
- 2010-10-11 BR BR112012008485A patent/BR112012008485A2/pt not_active IP Right Cessation
- 2010-10-11 KR KR1020127012100A patent/KR20120081210A/ko not_active Ceased
-
2012
- 2012-02-09 IL IL218018A patent/IL218018A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IN2012DN02487A (OSRAM) | 2015-08-28 |
| IL218018A0 (en) | 2012-04-30 |
| US20110086854A1 (en) | 2011-04-14 |
| JP2013507416A (ja) | 2013-03-04 |
| MX2012003982A (es) | 2012-05-08 |
| CA2774512A1 (en) | 2011-04-21 |
| US8017607B2 (en) | 2011-09-13 |
| KR20120081210A (ko) | 2012-07-18 |
| EP2488491A1 (en) | 2012-08-22 |
| AU2010305914A1 (en) | 2012-03-08 |
| WO2011045257A1 (en) | 2011-04-21 |
| CN102548963A (zh) | 2012-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012008485A2 (pt) | composto, formulação farmacêutica, uso de um composto, processo para a fabricação do composto de formula e compostos, processos, formulações e usos | |
| BRPI1006162A2 (pt) | "composto,processo para preparar um composto,formulação farmacêutica,e uso de um composto". | |
| BRPI0906475A2 (pt) | Compostos, processso para a preparação de um composto, composição farmacêutica e uso de um composto | |
| BRPI0818533A2 (pt) | composto, composição farmacêutica, e, processo para a preparação de um composto | |
| BR112014007134A2 (pt) | usos de um composto da fórmula (b), compostos, composição farmacêutica, método de preparação do composto e uso de uma quantidade efetiva de um composto | |
| BRPI0817423A2 (pt) | Processos para a preparação de um composto, para a preparação de uma formulação farmacêutica, e para a preparação de um intermediário de um composto, e, composto | |
| BR112013016761A2 (pt) | uso de um composto, composto da fórmula, composição farmacêutica, oligonucleotídeo, conjugado de molécula pequena e um oligonucleotídeo, compostos, uso e métodos | |
| BR112013028959A2 (pt) | composto, processo para o preparo de um composto, combinação de um composto, composição farmacêutica, uso de um composto, dispositivo e kit | |
| BR112013030163A2 (pt) | composto, uso cosmético de pelo menos um composto, composição farmacêutica ou cosmética e processo para preparar um composto. | |
| BR112014002499A2 (pt) | compostos, processos para a preparação de compostos de fórmula i, composições agroquímicas e usos de compostos de fórmula i ou viii | |
| BRPI0914927A2 (pt) | composto, composição farmacêutica, métodos para inibir a função de fak e de tratamento de um câncer, uso de um composto, e, processo para preparar um composto | |
| BR112014010206A2 (pt) | composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença | |
| BRPI0816991A2 (pt) | Formulação, processo para preparar a mesma, e, usos de uma composição antimicrobiana e de uma formulação | |
| BR112014029530A2 (pt) | compostos, composição farmacêutica e uso de um composto | |
| BRPI0816331A2 (pt) | Composto, uso de um composto, composição farmacêutica, e, processo para preparar um composto. | |
| BRPI1016219A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BRPI1008793A2 (pt) | composto, uso de um composto, e, composição farmacêutica | |
| BR112012016201A2 (pt) | ''composto, processo para a preparação de um composto, composição farmacêutica e uso de um composto'' | |
| BRPI0908221A2 (pt) | processo para preparar uma formulação farmacêutica de agentes de contraste | |
| BR112013009486A2 (pt) | processo para preparação de formas de dosagem gastrirretentivas multiparticuladas | |
| BRPI0908738A2 (pt) | composto, medicamento, uso de um composto, e, processo para preparar os compostos | |
| BRPI0922714A2 (pt) | composto, processo para preparar um compsoto, medicamento, uso de um composto, e, composição farmacêutica | |
| BR112014013354A2 (pt) | processo para a preparação de um polímero, composição, composto, e, formulação | |
| BRPI0817889A2 (pt) | Composição farmacêutica, composto misto de metal para uso como um medicamento, uso de um composto misto de metal, e, processo para a produção de um composto misto de metal esgotado de magnésio | |
| BRPI1010933A2 (pt) | processo para a preparação de um pó, e, composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |